<DOC>
	<DOCNO>NCT02235701</DOCNO>
	<brief_summary>This Phase 1 open-label study study safety activity aldoxorubicin ifosfamide/mesna subject metastatic , advanced , unresectable soft tissue sarcoma .</brief_summary>
	<brief_title>Study Investigate Safety Activity Aldoxorubicin Plus Ifosfamide/Mesna Subjects With Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Age 1580 year , male female . 2 . Adjuvant neoadjuvant chemotherapy ( include doxorubicin ) allow tumor recurrence least 12 month since last measurement , begin end last chemotherapy . 3 . Histologically cytologically confirm , locally advanced , unresectable , and/or metastatic soft tissue sarcoma ( include rhabdomyosarcoma , Ewing 's sarcoma mixed mesodermal sarcoma ) , chondrosarcoma osteosarcoma intermediate high grade gastrointestinal stromal tumor ( GIST ) ( subject progress receive treatment imatinib sunitinib ) . 4 . Capable provide informed consent comply trial procedure . 5 . ECOG performance status 02 . 6 . Life expectancy &gt; 12 week . 7 . Measurable tumor lesion accord RECIST 1.1 criterion . 8 . Women must able become pregnant ( eg postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . ( Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ) 9 . Males female partner ( ) childbearing potential must use 2 form effective contraception ( see Inclusion 8 plus condom vasectomy male ) last menstrual period female partner study treatment 6 month final dose study treatment . 10 . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . 11 . Geographic accessibility site ensures subject able keep studyrelated appointment . 1 . Prior chemotherapy unless adjuvant neoadjuvant therapy tumor recurrence least 12 month . 2 . Prior exposure &gt; 3 cycle 225 mg/m2 doxorubicin Doxil® . 3 . Palliative surgery and/or radiation treatment le 30 day prior enrollment . 4 . Exposure investigational agent within 30 day enrollment . 5 . Current Stage 1 2 soft tissue sarcoma . 6 . Current evidence/diagnosis alveolar soft part sarcoma , dermatofibrosarcoma , Kaposi 's sarcoma , clear cell sarcomas unresectable low grade liposarcoma . 7 . Central nervous system metastasis symptomatic . 8 . History malignancy except cure basal cell carcinoma , superficial bladder cancer carcinoma situ cervix unless document free cancer ≥ 5 year . 9 . Laboratory value : Screening serum creatinine &gt; 1.5x upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 3 × ULN &gt; 5 × ULN liver metastasis present , total bilirubin &gt; 3 × ULN , absolute neutrophil count &lt; 1,500/mm3 , platelet concentration &lt; 100,000/mm3 , hematocrit level &lt; 25 % female &lt; 27 % male , albumin &lt; 2 gm/dL , coagulation test ( prothrombin time [ PT ] , partial thromboplastin time [ PTT ] , International Normalized Ratio [ INR ] ) &gt; 1.5 × ULN . 10 . Clinically evident congestive heart failure &gt; class II New York Heart Association ( NYHA ) guideline .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>aldoxorubicin</keyword>
	<keyword>ifosfamide</keyword>
	<keyword>mesna</keyword>
	<keyword>phase 1</keyword>
	<keyword>INNO-206</keyword>
</DOC>